Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg, JC Yang, NP Restifo - Nature medicine, 2004 - nature.com
SA Rosenberg, JC Yang, NP Restifo
Nature medicine, 2004•nature.comGreat progress has been made in the field of tumor immunology in the past decade, but
optimism about the clinical application of currently available cancer vaccine approaches is
based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine
trials of 440 patients, the objective response rate was low (2.6%), and comparable to the
results obtained by others. We consider here results in cancer vaccine trials and highlight
alternate strategies that mediate cancer regression in preclinical and clinical models.
optimism about the clinical application of currently available cancer vaccine approaches is
based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine
trials of 440 patients, the objective response rate was low (2.6%), and comparable to the
results obtained by others. We consider here results in cancer vaccine trials and highlight
alternate strategies that mediate cancer regression in preclinical and clinical models.
Abstract
Great progress has been made in the field of tumor immunology in the past decade, but optimism about the clinical application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clinical tumor regression. In our cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others. We consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclinical and clinical models.
nature.com